Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

Welcome — one more step

News Plus opens the cross-newsroom layer — who covered a story, who didn’t, and how each one worded it.

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email
  • Headlines side by side
  • Who reported first
  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Live Terminal

Eligible new subscribers get 7 days free, then $34.99 each year. Renews automatically until cancelled. Cancel any time in your account. Subscription terms.

Your subscription also unlocks the app.

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to save this article and find it on your phone.

or use an email code

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

Choose the alerts that matter to you

News Plus includes topic, person and story alerts, and your own coverage surge threshold.

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email
  • Headlines side by side
  • Who reported first
  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Live Terminal
See News Plus
Health · Full coverage

Israeli Firm DreamD Receives FDA Approval for Diabetes App

How 3 Israeli newsrooms covered this story — translated into English and compared side by side.

Center 1Unrated 2

By בן פלמון

What happened

Israeli company DreamD secured FDA approval for its Modi app, which provides personalized insulin dosage recommendations for type 2 diabetes patients using injections. The app analyzes glucose and insulin data to offer guidance between doctor visits.

  • 01Israeli company DreamD's Modi app received FDA approval for type 2 diabetes patients.
  • 02The app provides personalized insulin dosage recommendations via smartphone.
  • 03It analyzes continuous glucose monitoring and insulin treatment data.
  • 04Modi is the first FDA-approved solution for insulin injection users.
  • 05The app is named after Mordechai 'Modi' Amir, killed on October 7.

Summary translated & synthesized from the sources below by baba. Read each original for the full report.

Ask About This Story

Duki reads it, and every newsroom on the same story, then answers with sources.

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

Keep the whole picture

News Plus opens the cross-newsroom layer — who covered a story, who didn’t, and how each one worded it.

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email
  • Headlines side by side
  • Who reported first
  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Live Terminal

Eligible new subscribers get 7 days free, then $34.99 each year. Renews automatically until cancelled. Cancel any time in your account. Subscription terms.

Your subscription also unlocks the app.

In this story
OrganizationsFDA, DreamD, Next October

Full coverage · 3 outlets

The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.

BizportalUnrated · Hebrew22 minutes ago
Israeli Firm DreamD Receives FDA Approval for Diabetes App
CalcalistUnrated · Hebrew1 hour ago
Israeli App MODI Receives FDA Clearance for Insulin Dose Adjustments
i24NEWSCenter · Hebrew1 hour ago
Israeli Diabetes App MODI Secures FDA Approval for Type 2 Patients